查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1676771

视网膜静脉阻塞治疗市场：2025-2030 年全球预测（依治疗类型、年龄层、疾病类型和最终用户）

Retinal Vein Occlusion Treatment Market by Treatment Type, Age Group, Condition Type, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

视网膜静脉阻塞治疗市场预计在 2024 年价值为 29.1 亿美元，在 2025 年成长至 30.9 亿美元，复合年增长率为 6.44%，到 2030 年将达到 42.3 亿美元。

主要市场统计数据
基准年 2024 年 29.1亿美元
预计 2025 年 30.9亿美元
预测年份 2030 42.3亿美元
复合年增长率（%） 6.44%

在医学影像技术的进步和快速发展的治疗方法的推动下，视网膜静脉阻塞治疗市场经历了重大变化。过去几年为突破性的研究和临床资料铺平了道路，正在重塑我们治疗视网膜血管疾病的方式。该分析提供了对当前市场动态、新兴趋势和成长机会的全面概况。了解治疗方案的历史背景并说明新治疗性介入如何影响患者结果。现在，人们正在透过将科学进步与临床实用性无缝结合的创新解决方案来解决根深蒂固的市场挑战。如今，患者管理越来越趋向个人化，技术进步在改善不同患者群体的治疗技术方面发挥关键作用。此外，不断发展的临床方案和治疗方案正在增强整体状况。本执行摘要旨在清晰简洁地概述行业现状，解决不断变化的期望、竞争压力和监管变化，这些变化将继续影响临床决策和投资前景。

改变视网膜静脉阻塞治疗市场

近年来，视网膜静脉阻塞治疗领域发生了重大变化，治疗方法的突破性进展重新定义了临床实践。从复杂的注射技术到适应性皮质类固醇製剂的开发，治疗技术的不断进步有助于提高针对视网膜疾病根本原因的精准度。同时，雷射疗法与创新药物相结合的联合疗法的疗效正在临床试验中进行检验，以提高治疗的安全性和有效性。监管机构也开始为新治疗方法的核准提供更清晰的途径，增强相关人员的信心并鼓励研究资金的涌入。这些变化不仅能更有效地将实验室发现转化为临床实践，而且促进医疗设备製造商、製药公司和执业医师之间的合作。治疗方法的快速发展反映了整个行业对个人化医疗的关注，其中明确的诊断和针对患者的治疗计划至关重要。透过接受这种变革性转变，市场参与者将自己定位在一个动态领域的最前沿，该领域正在不断发展以满足老龄化和越来越注重健康的患者群体的需求。

这些不断发展的策略凸显了该行业致力于解决护理差距和改善长期患者治疗效果的承诺。速度、创新和监管进步的结合为现有企业和新参与企业创造了前所未有的商业机会。

关键细分市场洞察

对市场区隔的详细研究揭示了对于理解视网膜静脉阻塞治疗的范围和规模至关重要的几个关键方面。第一个向度是治疗类型，检视抗 VEGF 注射、皮质类固醇治疗和雷射治疗方式的市场。在抗 VEGF 注射类别中，治疗方法进一步分为特定药物，例如阿柏西普、Bevacizumab和雷珠单抗，每种药物在功效和市场渗透率方面都表现出自己的特征。另一个方面是年龄组细分，它揭示了不同人口统计的治疗考虑，对 40-60 岁、60 岁以上和 40 岁以下的分析可以得出关键见解。此分类明确区分了视网膜分支静脉阻塞症和视网膜中央静脉阻塞，突显了临床表现和治疗结果的差异。最后，透过最终用户细分的角度了解市场动态，可以明确门诊手术中心、医院和专科诊所所扮演的不同角色。这些细分见解突显了可用的治疗方法以及患者群体的异质性，使相关人员能够更好地客製化干预措施并有效分配资源。总体而言，細項分析不仅有助于更准确地预测市场趋势，而且也是製定不断发展的医疗保健策略的重要工具。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 糖尿病和高血压等风险因素的增加意味着需要有效的治疗方法
      • 医疗成本上涨促使人们投资视网膜静脉阻塞治疗方案
    • 限制因素
      • 视网膜静脉阻塞治疗费用高且报销政策有限
    • 机会
      • 基因治疗技术在视网膜静脉阻塞长期治疗的持续进展
      • 人工智慧在视网膜静脉阻塞早期发现与个人化治疗计画的应用
    • 任务
      • 视网膜静脉阻塞治疗患者管理中的併发症
  • 市场区隔分析
    • 治疗类型：抗 VEGF 注射广泛用于治疗黄斑部水肿。
    • 疾病类型：视网膜分支静脉阻塞症发生率不断上升，导致晚期治疗需求增加
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 视网膜静脉阻塞治疗市场（依治疗类型）

  • 抗 VEGF 注射剂
    • 阿柏西普
    • Bevacizumab
    • 雷珠单抗
  • 皮质类固醇治疗
  • 雷射治疗

第七章 视网膜静脉阻塞治疗市场（依年龄层）

  • 40-60
  • 年龄 60 岁或以上
  • 40岁以下

第 8 章视网膜静脉阻塞治疗市场（依症状类型）

  • 视网膜分支静脉阻塞症
  • 视网膜中央静脉阻塞

第 9 章视网膜静脉阻塞治疗市场（依最终使用者）

  • 门诊手术中心（ASC）
  • 医院
  • 专科门诊

10.美洲视网膜静脉阻塞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区视网膜静脉阻塞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲视网膜静脉阻塞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • AbbVie
  • Alimera Sciences, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Carl Zeiss AG
  • Fovea Pharmaceuticals SA
  • Genentech, Inc.
  • GlaxoSmithKline plc
  • IRIDEX Corporation
  • Johnson & Johnson Services, Inc.
  • Lumenis Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Ranbaxy Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Suzuken Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-B570E7E0C832

The Retinal Vein Occlusion Treatment Market was valued at USD 2.91 billion in 2024 and is projected to grow to USD 3.09 billion in 2025, with a CAGR of 6.44%, reaching USD 4.23 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.91 billion
Estimated Year [2025] USD 3.09 billion
Forecast Year [2030] USD 4.23 billion
CAGR (%) 6.44%

The retinal vein occlusion treatment market has experienced significant evolution, driven by advances in medical imagery and rapidly emerging therapeutic modalities. In the past few years, research and clinical data have paved the way for breakthroughs that are reshaping how retinal vascular disorders are addressed. This analysis provides a comprehensive overview of current market dynamics along with emerging trends and opportunities for growth. The discussion navigates through the historical context of treatment options and explains the impact of novel therapeutic interventions on patient outcomes. The market's deep-rooted challenges are now being met with innovative solutions that seamlessly combine scientific advancement with clinical practicality. Today, patient management is increasingly characterized by a personalized approach, and technological advancements have played a pivotal role in refining administration techniques across diverse patient populations. Moreover, the evolution of clinical protocols and therapeutic regimes has bolstered the overall landscape. This executive summary aims to offer a clear and concise synthesis of the industry's status while addressing evolving expectations, competitive pressures, and regulatory changes that continue to shape clinical decisions and investment prospects.

Transformative Shifts in the Landscape

Recent years have witnessed transformative shifts within the retinal vein occlusion treatment landscape, as breakthroughs in therapeutic modalities now redefine clinical practices. Continuous advancements in treatment technologies-ranging from refined injection techniques to the development of adaptive corticosteroid formulations-facilitate enhanced precision in targeting the underlying causes of retinal damage. In parallel, clinical trials are increasingly validating the effectiveness of combination approaches that integrate laser therapy with innovative pharmacological agents, thereby improving both the safety and efficacy profiles of treatments. Regulatory bodies have also begun to provide clearer pathways for the approval of emerging therapies, which has bolstered confidence among stakeholders and led to an influx of research funding. These changes are not only facilitating a more efficient translation of laboratory findings into clinical solutions but are also encouraging collaborations among medical device manufacturers, pharmaceutical companies, and practitioners. The swift evolution in treatment methodologies reflects an industry-wide focus on personalized medicine, where diagnostic clarity and patient-specific treatment plans are paramount. By embracing these transformative shifts, market players are positioning themselves at the forefront of a dynamic space that continuously evolves to meet the needs of an aging and increasingly health-conscious patient demographic.

These evolving strategies underscore the commitment of the industry to address gaps in care and improve long-term patient outcomes. It is a landscape where speed, innovation, and regulated progress converge to create unprecedented opportunities for both incumbents and newer entrants.

Key Segmentation Insights

An in-depth study of the market's segmentation reveals several critical dimensions that are vital for understanding the scope and scale of retinal vein occlusion treatment. The first dimension examines treatment type, where the market is studied across anti-VEGF injection, corticosteroid treatment, and laser therapy modalities. Within the anti-VEGF injection category, therapies are further delineated into specific drugs such as Aflibercept, Bevacizumab, and Ranibizumab, each presenting its own distinct profile in terms of efficacy and market penetration. In another dimension, age group segmentation sheds light on treatment considerations across varying demographics, with key insights emerging from analysis among individuals aged between 40-60, those above 60, and even those below 40. Thirdly, the segmentation based on condition types is crucial; the classification distinctly separates branch retinal vein occlusion from central retinal vein occlusion, highlighting differences in clinical presentation and treatment outcomes. Lastly, understanding market dynamics through the lens of end user segmentation provides clarity regarding the varied roles played by ambulatory surgical centers, hospitals, and specialty clinics. These segmentation insights collectively emphasize the heterogeneity of the patient population as well as the therapeutic approaches available, situating stakeholders to better tailor interventions and allocate resources effectively. Overall, the segmentation analysis not only enhances predictive accuracy for market trends but also serves as a critical tool for strategy formulation within this evolving healthcare landscape.

Based on Treatment Type, market is studied across Anti-VEGF Injection, Corticosteroid Treatment, and Laser Therapy. The Anti-VEGF Injection is further studied across Aflibercept, Bevacizumab, and Ranibizumab.

Based on Age Group, market is studied across 40-60, Above 60, and Below 40.

Based on Condition Type, market is studied across Branch Retinal Vein Occlusion and Central Retinal Vein Occlusion.

Based on End User, market is studied across Ambulatory Surgical Centers (ASCs), Hospitals, and Specialty Clinics.

Key Regional Insights

A regional analysis uncovers significant variances in market dynamics across key geographies. Insights drawn from the Americas reveal thriving ecosystems bolstered by robust healthcare systems and sustained investments in ophthalmological research, positioning the area as a leader in clinical innovations. In regions spanning Europe, the Middle East, and Africa, regulatory frameworks and collaborative initiatives among public and private sectors drive consistent progress in treatment uptake and research. Meanwhile, the Asia-Pacific region is characterized by accelerating advancements in technology and a rapidly expanding patient base, which in turn fuels higher demand for affordable and effective treatment options. Across these regions, trends in healthcare expenditure and patient-centric innovations have laid the groundwork for exponential growth in clinical services, while demographic shifts and an increasing prevalence of chronic conditions further underscore the significance of these findings. The analysis highlights that each geographical zone brings unique perspectives and challenges, yet all are aligned around the central goal of improving clinical outcomes through state-of-the-art therapeutic interventions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights

An examination of the competitive landscape identifies a cohort of prominent companies that are at the forefront of advancing retinal vein occlusion treatments. Leading innovators such as AbbVie, Alimera Sciences, Inc., Bayer AG, and Bristol-Myers Squibb Company have been actively engaged in research-driven advancements that shape market strategies and therapeutic outcomes. These industry players are complemented by other significant contributors including Carl Zeiss AG, Fovea Pharmaceuticals SA, Genentech, Inc., and GlaxoSmithKline plc, each bringing specialized expertise that reinforces market progress. Companies like IRIDEX Corporation and Johnson & Johnson Services, Inc. have leveraged technological advancements to streamline treatment protocols, while Lumenis Ltd. and Novartis AG continue to drive innovation through precision-based methodologies. Further, the contributions of Pfizer Inc., Ranbaxy Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Suzuken Co., Ltd., and Teva Pharmaceutical Industries Ltd. ensure a competitive balance. Their continued focus on product quality, clinical safety, and global outreach creates a landscape that is dynamic, competitive, and ripe for new innovations. This collective focus on research, strategic partnerships, and robust product pipelines is central to understanding the current market structure and anticipating future developments in treatment modalities.

The report delves into recent significant developments in the Retinal Vein Occlusion Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Alimera Sciences, Inc., Bayer AG, Bristol-Myers Squibb Company, Carl Zeiss AG, Fovea Pharmaceuticals SA, Genentech, Inc., GlaxoSmithKline plc, IRIDEX Corporation, Johnson & Johnson Services, Inc., Lumenis Ltd., Novartis AG, Pfizer Inc., Ranbaxy Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Suzuken Co., Ltd., and Teva Pharmaceutical Industries Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders must adopt agile and forward-thinking strategies that address both current challenges and future opportunities in retinal vein occlusion treatment. Emphasis should be placed on investing in innovation and integrating advanced therapeutic techniques, particularly in the realm of anti-VEGF injections and laser therapy enhancements, while remaining vigilant about the evolving competitive landscape. Leaders are encouraged to foster collaborations across research institutions and clinical networks to leverage emerging data for more effective patient outcomes. A strategic focus on tailoring treatment approaches to distinct patient segments, with an acute understanding of age-based nuances and specific condition types, lies at the heart of optimizing clinical efficacy. Furthermore, prioritizing investments in technology infrastructure is crucial to sustain competitive advantage in a market that rapidly evolves due to digital and data-driven healthcare innovations. Comprehensive commercial strategies should also incorporate risk assessment, regulatory compliance, and marketing initiatives that resonate with diverse end users including hospitals, ambulatory centers, and specialty clinics. Proactive engagement with key opinion leaders and incorporation of real-world evidence into decision-making processes can further enhance market positioning. Ultimately, a balance between clinical excellence and business agility is essential for preserving market leadership while adapting to emerging clinical trends and patient demands.

Conclusion: Strategic Considerations for the Future

The evolution of retinal vein occlusion treatment underscores a fundamental shift toward precision, patient-centric approaches, and innovation-driven growth. Advancements in therapeutic modalities, coupled with a nuanced understanding of market segmentation and regional trends, are defining the framework of this dynamic market. Key insights into treatment types, patient demographics, clinical conditions, and operational channels not only enhance the strategic positioning of industry players but also foster a competitive environment that incentivizes continuous improvement. As we look to the future, embracing technological progress and maintaining a clear focus on clinical excellence will be paramount in achieving sustained success. Stakeholders must therefore harness emerging insights, collaborative frameworks, and regulatory progress to drive forward innovation and operational efficiency in this ever-evolving field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of risk factors such as diabetes and hypertension necessitating effective therapies
      • 5.1.1.2. Rising healthcare expenditure encouraging investment in retinal vein occlusion treatment options
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with retinal vein occlusion treatment & limited reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advances in gene therapy techniques for long-term management of retinal vein occlusion
      • 5.1.3.2. Adoption of artificial intelligence in early detection and personalized treatment plans for retinal vein occlusion
    • 5.1.4. Challenges
      • 5.1.4.1. Comorbidities complication in patient management for retinal vein occlusion treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment Type: Wide adoption of anti-VEGF injections to manage macular edema
    • 5.2.2. Condition Type: Growing prevalence of branch retinal vein occlusion boosting demand for advanced treatments
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Retinal Vein Occlusion Treatment Market, by Treatment Type

  • 6.1. Introduction
  • 6.2. Anti-VEGF Injection
    • 6.2.1. Aflibercept
    • 6.2.2. Bevacizumab
    • 6.2.3. Ranibizumab
  • 6.3. Corticosteroid Treatment
  • 6.4. Laser Therapy

7. Retinal Vein Occlusion Treatment Market, by Age Group

  • 7.1. Introduction
  • 7.2. 40-60
  • 7.3. Above 60
  • 7.4. Below 40

8. Retinal Vein Occlusion Treatment Market, by Condition Type

  • 8.1. Introduction
  • 8.2. Branch Retinal Vein Occlusion
  • 8.3. Central Retinal Vein Occlusion

9. Retinal Vein Occlusion Treatment Market, by End User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers (ASCs)
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Retinal Vein Occlusion Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Retinal Vein Occlusion Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Retinal Vein Occlusion Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. European Commission approves groundbreaking Vabysmo treatment, revolutionizing retinal vein occlusion care across the EU
    • 13.3.2. Health Canada approves Vabysmo for retinal vein occlusion
    • 13.3.3. Chugai's Vabysmo secures approval as the first bispecific antibody for retinal vein occlusion treatment in Japan
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie
  • 2. Alimera Sciences, Inc.
  • 3. Bayer AG
  • 4. Bristol-Myers Squibb Company
  • 5. Carl Zeiss AG
  • 6. Fovea Pharmaceuticals SA
  • 7. Genentech, Inc.
  • 8. GlaxoSmithKline plc
  • 9. IRIDEX Corporation
  • 10. Johnson & Johnson Services, Inc.
  • 11. Lumenis Ltd.
  • 12. Novartis AG
  • 13. Pfizer Inc.
  • 14. Ranbaxy Pharmaceuticals Inc.
  • 15. Regeneron Pharmaceuticals, Inc.
  • 16. Sanofi S.A.
  • 17. Suzuken Co., Ltd.
  • 18. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. RETINAL VEIN OCCLUSION TREATMENT MARKET MULTI-CURRENCY
  • FIGURE 2. RETINAL VEIN OCCLUSION TREATMENT MARKET MULTI-LANGUAGE
  • FIGURE 3. RETINAL VEIN OCCLUSION TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 4. RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. RETINAL VEIN OCCLUSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. RETINAL VEIN OCCLUSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RETINAL VEIN OCCLUSION TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RETINAL VEIN OCCLUSION TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CORTICOSTEROID TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY 40-60, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ABOVE 60, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BELOW 40, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY BRANCH RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CENTRAL RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS (ASCS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY ANTI-VEGF INJECTION, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY CONDITION TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM RETINAL VEIN OCCLUSION TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 235. RETINAL VEIN OCCLUSION TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 236. RETINAL VEIN OCCLUSION TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024